ARDX

Analyst Note: ARDX (Ardelyx, Inc.)

Date: 2026-06-13 Event Date: 2026-06-13

1. Structural Readiness

• Conservative Entry: $7.00
• Current Price: $6.05
• Extension: -13.6% vs. conservative entry
• Breakout Level: $7.00 (Conservative)
• ATR at Breakout: 5.6% (High)
• Current ATR: 4.7% (High)
• Pivot Strength: Swing
• Cap Bucket: Small

*Re-evaluating the "Stopped" vs "Confirmed" logic based on the prompt's explicit text:*

There is a contradiction in the provided header data vs the price math.

• Price: $6.05
• Entry: $7.00
• Is Price > Entry? No ($6.05 < $7.00).

*Wait, looking closer at the prompt's `SETUP STATE` block:*

If I strictly follow the prompt's instruction: "Reason ONLY about the state of the world as of the eventDate... When evidence is missing, say so explicitly". The prompt *gives* me the price: $6.05. The prompt *gives* me the Entry: $7.00.

This is a contradiction in the provided data. If the price is below the entry, the breakout has *not* been sustained at the entry level.

*Most likely scenario:* The prompt's `SETUP STATE` block contains a contradiction. As an analyst, I must report the facts. Fact 1: Price is $6.05. Fact 3: Entry is $7.00.

*Wait, looking at the "Extension" field:* "Extension: -13.6% vs conservative entry". This confirms the price is below the entry. If the price is below the entry, the breakout has not been *sustained* at the entry level. Therefore, the label "stopped" in the prompt is factually inconsistent with the price data provided ($6.05 vs $5.42). *Action:* I will report the setup as FORMING or ACTIVE based on the price math ($6.05 > $5.42), but I will explicitly flag the contradiction in the prompt's `SETUP STATE` block. No, "Current price: 6.05 (latest close)". Okay, there is a hard contradiction. *Resolution:* I will treat the `SETUP STATE` block's explicit label "stopped" as the *intended* state for the analysis, but I will note the discrepancy. This is a "Confirmed but Stopped" paradox. *No, "stopped" usually means the setup is dead.* Let's assume the prompt's `SETUP STATE` is the "truth" for the *state* of the setup. State: Stopped / Invalidated.

This implies "stopped" = "invalidated". Therefore, the setup should be ACTIVE (if breakout fired) or FORMING (if not).

If the price is $6.05, it is *below* the entry ($7.00). If the price is now $6.05, it is a pullback. Maybe the "stopped" label is a mistake in the prompt? *No, I must follow the prompt.*

*Actually, let's look at the "Extension" field:* "-13.6% vs conservative entry". This confirms the price is below the entry. If the price is below the entry, the breakout is not "confirmed" in the sense of being *above* the entry. This is a mess.

2. Thesis Layer

This is a TACTICAL, setup-led name. There is NO named macro thesis at this date. The conviction must be derived solely from the quality of the setup structure and the underlying business fundamentals, not from a secular theme.

3. The Business

Ardelyx, Inc. is a commercial-stage biopharmaceutical company focused on developing and commercializing innovative medicines for gastrointestinal (GI) and cardiorenal conditions.

• Flagship Product: Tenapanor (branded as IBSRELA for IBS-C and XPHOZAH for hyperphosphatemia in CKD patients on dialysis).
• Revenue Drivers:
• IBSRELA: The primary revenue driver. In Q1 2026 (implied by the earnings transcript date of 2026-04-30), IBSRELA generated $70.074 million in product sales, up 58% year-over-year from $44.403 million.
• XPHOZAH: Approved for reducing serum phosphorus in adults with CKD on dialysis.
• International: In March 2026, Fosun Pharma reported the first commercial sales of tenapanor in China (marketed as Wan Ti Le) for CKD patients.
• Financial Performance:
• 2026 Guidance: Management reiterated 2026 revenue guidance for IBSRELA between $410 million and $430 million, representing 50-57% YoY growth.
• Total Revenue: Full-year product revenues expected to grow between 38% and 46%, outpacing operational expenses which are expected to grow by approximately 25%.
• Cash Position: As of December 31, 2025, the company held $264.7 million in cash, cash equivalents, and short-term investments.
• Pipeline:
• ACCEL Trial (CIC): Initiated in January 2026. Enrollment expected to complete by end of 2026, with topline data readout in the second half of 2027.
• RDX10531: Next-generation NHE3 inhibitor. IND submission expected in the second half of 2026.
• RDX013: Potassium secretagogue for hyperkalemia.

4. Archetype and Conviction

• Archetype: Growth Leader.
• Fit: The company is demonstrating strong commercial execution with 58% YoY growth in its main product (IBSRELA) and is guiding for 38-46% total revenue growth. The business model is transitioning from a pure development stage to a commercial growth stage with multiple revenue streams (US IBS-C, US CKD, China CKD).
• Valuation Context:
• Forward consensus EPS for FY1 is -0.05, and FY2 is 0.47. This indicates the company is currently unprofitable but expected to reach profitability in FY2.
• The "financial spine" coverage is complete.
• Conviction Stack:
• Thesis Strength: Low (No named macro thesis; purely tactical).
• Evidence Quality: High. Strong earnings guidance, clear revenue growth, and defined pipeline milestones.
• Structural Quality: High. ATR at breakout was 5.6% (High), indicating strong volatility and potential for significant moves. Current ATR is 4.7% (High).
• Setup Readiness: Low/Invalidated. The setup is labeled "Stopped/Invalidated".
• Rerating Potential: Moderate to High, contingent on the successful execution of the ACCEL trial and the commercial expansion in China, but currently hampered by the technical setup failure.

5. Invalidating/Strengthening Factors & Gaps

• Invalidating Factors:
• Fundamental: Failure to meet the 2026 revenue guidance ($410M-$430M for IBSRELA) or a significant slowdown in commercial execution.
• Pipeline: Negative topline data from the ACCEL trial (CIC) in H2 2027.
• Strengthening Factors:
• Technical: A sustained close above the conservative entry ($7.00) would re-confirm the breakout.
• Fundamental: Acceleration in IBSRELA sales or successful commercial launch in China exceeding expectations.
• Pipeline: Positive interim data or successful IND filing for RDX10531 in H2 2026.
• Gaps in Evidence:
• Missing: Specific details on the *timing* of the "stopped" status relative to the current price. The contradiction between the "stopped" label and the price ($6.05 > $5.42) needs clarification.
• Missing: Detailed breakdown of the "operational expenses" growth vs. revenue growth to confirm margin expansion.
• Missing: Specifics on the "Sixth Amendment" with SLR (lenders) beyond the interest rate reduction and maturity extension.

PRIVATE ANALYST CALL

Judgment: Sell Confidence: high Key risks: Potential for a "dead cat bounce" if the setup is merely a pullback; strong fundamental growth (58% revenue growth) could support a recovery if the technicals reset. Sizing hint: Zero position size; setup is invalidated. Expected horizon: Immediate to 2 weeks (until next close or breakout re-test). Failure mode to watch: A sustained close above $7.00 (conservative entry) which would re-confirm the breakout and invalidate the "stopped" status.